Bio‑Techne (TECH) director reports 1,640 shares, 3,777 options

Bio‑Techne (TECH) director Judith V. Klimovsky filed a Form 4 reporting equity awards.

Accepted by SEC EDGAR 11/03/2025 - 05:23 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Bio‑Techne (TECH) director Judith V. Klimovsky filed a Form 4 reporting equity awards. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing direct holdings to 3,782 shares.

She was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring 10/30/2035. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders. Existing options include 1,610 at $73.46 (exp. 05/01/2034) and 3,511 at $68.37 (exp. 10/24/2034).

Insider Trade Summary

Grant/Award: 5,417 shares

Grant/Award 2 txns

Insider Klimovsky Judith V.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,777	$0.00	$0.00
Grant/Award	Common Stock	1,640	$0.00	$0.00
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,898 contracts for 5,121 underlying shares (Direct); Common Stock — 3,782 shares (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BIO-TECHNE (TECH) disclose in this Form 4?

Director Judith V. Klimovsky reported acquiring 1,640 common shares at $0 on 10/30/2025 and receiving a stock option for 3,777 shares at $60.96.

How many TECH shares does the reporting person hold after the transaction?

Directly held common shares total 3,782 following the reported transaction.

What are the key terms of the new stock option for TECH?

The option covers 3,777 shares at $60.96 and expires on 10/30/2035. It vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the 2026 annual meeting.

What other BIO-TECHNE options does the director hold?

Existing options include 1,610 at $73.46 (exp. 05/01/2034) and 3,511 at $68.37 (exp. 10/24/2034).

Was the stock acquisition under a 10b5-1 plan?

The form includes a checkbox for Rule 10b5‑1(c) plans; the excerpt does not indicate it was checked.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klimovsky Judith V.

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		A		1,640	A	$0	3,782	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$73.46							10/24/2024	05/01/2034	Common Stock	1,610		1,610	D
Stock Option (Right to Buy)	$68.37							10/24/2025	10/24/2034	Common Stock	3,511		3,511	D
Stock Option (Right to Buy)	$60.96	10/30/2025		A		3,777		(1)	10/30/2035	Common Stock	3,777	$0	3,777	D

Explanation of Responses:

1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

	/s/ Andrew Nick as Attorney-in-Fact for Judith V. Klimovsky pursuant to Power of Attorney filed previously.	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.